Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • الموضوع:
      Antibodies, Monoclonal, Humanized*/therapeutic use ; SARS-CoV-2*/immunology ; SARS-CoV-2*/genetics ; COVID-19 Drug Treatment* ; Spike Glycoprotein, Coronavirus*/immunology ; Spike Glycoprotein, Coronavirus*/genetics; Humans ; Retrospective Studies ; Male ; Female ; Middle Aged ; Aged ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Neutralizing/immunology ; COVID-19/immunology ; COVID-19/virology ; COVID-19/mortality ; Hospitalization ; Antiviral Agents/therapeutic use ; Adult ; Treatment Outcome ; Aged, 80 and over ; Drug Combinations
    • نبذة مختصرة :
      Background: Neutralizing antibodies targeting the SARS-CoV-2 Spike protein reduce COVID-19-related risk of hospitalization, particularly in high-risk individuals. The COCOPREV-R study aimed to evaluate and compare clinical outcomes in high-risk SARS-CoV-2 patients treated with dual monoclonal antibody therapies and to identify associated virological factors.
      Methods: The COCOPREV-R study retrospectively collected real-world data from high-risk patients receiving Bamlanivimab/Etesevimab or Casirivimab/Imdevimab dual monoclonal antibody therapies (22 February 2021 to 15 June 2021).
      Results: The study included 1004 patients with COVID-19, of whom 691 received Bamlanivimab/Etesevimab and 313 received Casirivimab/Imdevimab. The alpha variant represented 90.1% of those for whom data were available. The risk of hospitalization within 30 days was lower with Bamlanivimab/Etesevimab (12.7%, CI 95% [9.9-16.3%]) compared to Casirivimab/Imdevimab (28.4%, CI 95% [22.7-35.1%) ( p < 0.001). The 30-day mortality rates were comparable between both groups ( p = 0.982). Analysis of SARS-CoV-2 PCR negativity showed no difference between the two treatment groups (95.2% [93.0-96.9%] and 93.5% [89.1-96.6%] until day 30, p = 0.851 for Bamlanivimab/Etesevimab and Casirivimab/Imdevimab, respectively). Among persistently positive samples with available sequencing results ( n = 43), Spike protein changes occurred only in Bamlanivimab/Etesevimab (42.9%) vs. Casirivimab/Imdevimab (0.0%) groups. Q493R (25.0%) and E484K (12.5%) were the most common mutations selected by Bamlanivimab/Etesevimab in follow-up samples. Other factors (immunodepression, comorbidities, and age) did not appear to be associated with the occurrence of Spike protein mutations.
      Conclusions: A higher rate of hospitalization was seen with Casirivimab/Imdevimab (RONAPREVE ® ) in comparison with Bamlanivimab/Etesevimab treatment, but with the emergence of Spike mutations only in the Bamlanivimab/Etesevimab group.
    • References:
      J Infect Dis. 2024 May 15;229(5):1341-1351. (PMID: 37996072)
      Lancet. 2022 Feb 12;399(10325):665-676. (PMID: 35151397)
      Diagnostics (Basel). 2022 Jun 20;12(6):. (PMID: 35741313)
      Drug Resist Updat. 2023 Nov;71:100991. (PMID: 37572569)
      Clin Infect Dis. 2021 Dec 6;73(11):2144-2145. (PMID: 34009286)
      Sci Rep. 2021 Oct 12;11(1):20274. (PMID: 34642465)
      N Engl J Med. 2021 Jan 21;384(3):238-251. (PMID: 33332778)
      Med. 2023 Oct 13;4(10):664-667. (PMID: 37837962)
      J Clin Invest. 2023 Mar 15;133(6):. (PMID: 36727404)
      Microbiol Spectr. 2022 Jun 29;10(3):e0178921. (PMID: 35638818)
      J Infect. 2022 Feb;84(2):248-288. (PMID: 34437928)
      Clin Infect Dis. 2022 Aug 24;75(1):e440-e449. (PMID: 34718468)
      Lancet Microbe. 2021 Jul;2(7):e283-e284. (PMID: 33846703)
      Lancet Infect Dis. 2022 Nov;22(11):e311-e326. (PMID: 35803289)
      Cell. 2021 Apr 29;184(9):2362-2371.e9. (PMID: 33735608)
      N Engl J Med. 2021 Jan 21;384(3):229-237. (PMID: 33113295)
      Lancet Reg Health Eur. 2021 Sep;8:100164. (PMID: 34278371)
      N Engl J Med. 2021 Dec 2;385(23):e81. (PMID: 34587383)
      iScience. 2022 Apr 15;25(4):104076. (PMID: 35309727)
      Emerg Infect Dis. 2021 Oct;27(10):2728-2731. (PMID: 34314668)
      Viruses. 2021 Aug 19;13(8):. (PMID: 34452507)
      Viruses. 2022 Jan 24;14(2):. (PMID: 35215820)
      N Engl J Med. 2021 Oct 7;385(15):1382-1392. (PMID: 34260849)
    • Contributed Indexing:
      Keywords: COVID-19; SARS-CoV-2; immune escape mutation; monoclonal antibody therapy; spike gene
    • الرقم المعرف:
      0 (Antibodies, Monoclonal, Humanized)
      0 (Spike Glycoprotein, Coronavirus)
      0 (casirivimab and imdevimab drug combination)
      0 (Antibodies, Monoclonal)
      0 (Antibodies, Neutralizing)
      N7Q9NLF11I (etesevimab)
      0 (bamlanivimab and etesevimab drug combination)
      45I6OFJ8QH (bamlanivimab)
      0 (spike protein, SARS-CoV-2)
      0 (Antiviral Agents)
      J0FI6WE1QN (casirivimab)
      0 (Drug Combinations)
    • الموضوع:
      SARS-CoV-2 variants
    • الموضوع:
      Date Created: 20241026 Date Completed: 20241026 Latest Revision: 20241118
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC11512400
    • الرقم المعرف:
      10.3390/v16101542
    • الرقم المعرف:
      39459877